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The intracellular sensor NOD1 has important host-
defense functions relating to a variety of pathogens.
Here, we showed that this molecule also participates
in the induction of a noninfectious pancreatitis via
its response to commensal organisms. Pancreatitis
induced by high-dose cerulein (a cholecystokinin
receptor agonist) administration depends on NOD1
stimulation by gut microflora. To analyze this NOD1
activity, we induced pancreatitis by simultaneous
administration of a low dose of cerulein (that does
not itself induce pancreatitis) and FK156, an activator
of NOD1 that mimics the effect of gut bacteria that
have breached the mucosal barrier. The pancreatitis
was dependent on acinar cell production of the
chemokine MCP-1 and the intrapancreatic influx of
CCR2+ inflammatory cells. Moreover, MCP-1 pro-
duction involved activation of the transcription fac-
tors NF-kB and STAT3, each requiring complemen-
tary NOD1 and cerulein signaling. These studies
indicate that gut commensals enable noninfectious
pancreatic inflammation via NOD1 signaling in pan-
creatic acinar cells.
INTRODUCTION
Althoughmost episodes of acute pancreatitis aremild, a subpop-
ulation of patients with this condition develops a severe disease
with local and extrapancreatic complications (Frossard et al.,
2008). Bacterial colonization of the inflamed pancreas is involved
in the latter cases and, in fact, infection of necrotic pancreatic
tissue is one of the most important causes of mortality in acute
pancreatitis (Frossard et al., 2008). It is now generally accepted
that such colonization and associated inflammation result from
failure of intestinal-barrier function and translocation of intestinal326 Immunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc.microflora into the splanchnic vascular bed (Frossard et al.,
2008; Rychter et al., 2009).
Microbe-associated molecular patterns (MAMPs) derived
from the intestinal microflora activate the host innate immune
system via pattern-recognition receptors such as Toll-like recep-
tors (TLRs) and nucleotide-binding domain and leucine-rich
repeat containing molecules (NLRs) (Akira and Takeda, 2004;
Chen et al., 2009; Strober et al., 2006; Werts et al., 2011).
Thus, it is probable that activation of TLRs and NLRs is involved
in the mechanisms by which bacterial translocation accounts for
the development of severe acute pancreatitis. Consistent with
this idea, the severity of acute pancreatitis is ameliorated in
mice lacking TLR4 (Sharif et al., 2009), and polymorphism in
the TLR genes is associated with susceptibility to acute pancre-
atitis (Gao et al., 2007; Takagi et al., 2009). In addition, NF-kB,
a downstream transcription factor of the TLR and NLR signaling
pathways (Akira and Takeda, 2004; Strober et al., 2006), plays
a critical role in the development of acute pancreatitis (Baumann
et al., 2007; Rakonczay et al., 2008; Tando et al., 1999).
Studies have highlighted the role of the NLR family of proteins
in the microbial-recognition system that functions in the intes-
tinal milieu (Strober et al., 2006; Chen et al., 2009; Werts et al.,
2011). NOD1,which belongs to this family, is of particular interest
because it has been shown to play a protective role in infection
of the mucosal surface (Strober et al., 2006). NOD1 contains a
leucine-rich repeat region that serves as an intracellular sensor
of small peptide components derived from bacterial peptido-
glycan (PGN). Such recognition leads to NOD1 activation and
the production of proinflammatory mediators, either through
nuclear translocation of NF-kB or through interferon regulatory
factors (IRFs) and type I interferon signaling (Chamaillard et al.,
2003; Fritz et al., 2007; Watanabe et al., 2010).
The above properties of NOD1 suggest the possibility that this
NLR family member could contribute to the development of
noninfectious inflammatory states, particularly if it can be shown
that NOD1 responds to gut commensal organisms as well as to
pathogenic organisms (Girardin et al., 2003; Kim et al., 2004).
Here, we addressed this possibility by defining the role of
NOD1 in the development of cholecystokinin receptor (CCKR)
agonist-induced acute pancreatitis (cerulein pancreatitis). In
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of cerulein, a well-established inducer of pancreatitis, requires
the presence of gut commensal organisms acting through
NOD1 for the development of pancreatic inflammation. This
observation led us to develop a model of pancreatitis that would
allow us to define the role of NOD1 signaling in pancreatitis. This
consisted of the administration of low doses of cerulein that do
not in themselves cause pancreatitis and of the administration
of NOD1 ligand, which in this case could be shown to mimic
the activity of gut commensal bacteria that enter circulation
during pancreatitis. Using this model, we showed that NOD1
stimulation facilitates the migration of CCR2+ myeloid cells to
the pancreas in response to the robust acinar cell production
of monocyte chemotactic protein-1 (MCP-1); the latter, in turn,
results from cooperative NOD1-cerulein activation of NF-kB
and STAT3. Overall, these findings reveal that NOD1 signaling
plays a major role in the pathogenesis of cerulein-induced acute
pancreatitis via its capacity to respond to commensal gut
bacteria.
RESULTS
Bowel Sterilization by Broad-Spectrum Antibiotics
Inhibits High-Dose Cerulein Pancreatitis
Repeated administration of high doses of cerulein (50–
100 mg/kg), a CCKR agonist, is a well-established inducer of
acute murine pancreatitis (Baumann et al., 2007; Sharif et al.,
2009). To address the role of commensal organisms in the
intestinal microflora in the development of high-dose cerulein
pancreatitis, C57BL6 mice were administered a combination of
antibiotics (ampicillin [AMP], vancomycin, neomycin, and metro-
nidazole) in the drinking water for 3 weeks, a regimen previously
used to achieve bowel sterilization (Fagarasan et al., 2002), and
then challenged with repeated systemic intraperitoneal (i.p.)
injections of high doses of cerulein (50 mg/kg). We found that
mice administered normal drinking water and given seven hourly
injections of cerulein developed severe pancreatitis associated
with a marked increase in the serum concentrations of pancre-
atic enzymes, amylase, and lipase; in contrast, mice preadminis-
tered drinking water containing antibiotics developed barely
detectable pancreatic inflammation and onlymarginal elevations
in the serum concentrations of pancreatic enzymes (Figures 1A
and 1B). In complementary studies addressing the effects of a
single commensal organism, mice were first administered ampi-
cillin and kanamycin (KM) in the drinking water for 3 weeks and
then challenged with high doses of cerulein as before. We
observed that, even with this less stringent bowel-sterilization
regimen, the mice exhibited only a mild elevation in the serum
concentrations of amylase associated with normal pancreatic
architecture (Figures S1A and S1B available online). However,
high serum amylase concentrations and severe pancreatic
inflammation were again observed in mice that were adminis-
tered AMP- and KM-containing drinking water and underwent
periodic oral administration of AMP- and KM-resistant E. coli ex-
pressing LacZ (ECLACZ) (Yoshida et al., 2001) (Figures S1A and
S1B). In contrast, periodic oral administration of ECLACZ alone
did not induce a significant elevation of serum amylase levels
(Figure S1C) and, in addition, did not enhance elevated serum
amylase levels that were caused by administration of ceruleinin the absence of AMP and KM in the drinking water (Figure S1D).
Thus, ECLACZ used in this study behaved like a commensal
organism, with no capacity to induce pancreatitis on its own.
Taken together, these data provide strong evidence that
commensal organisms in the intestinal microflora are essential
for the development of acute pancreatitis caused by high-dose
cerulein.
NOD1 Activation Is Necessary for the Development of
High-Dose Cerulein Acute Pancreatitis
The above results suggested that an intestinal microbial compo-
nent recognized by a pattern-recognition receptor is important in
the development of high-dose cerulein pancreatitis. To investi-
gate this possibility, we compared serum concentrations of
amylase after high-dose cerulein injections, as described above,
in mice deficient in TLR2, TLR4, TLR9, or NOD1. Wild-type (WT)
mice, TLR2-deficient (Tlr2/) mice, and Tlr9/ mice all devel-
oped similar increases in the serum concentration of amylase,
suggesting that TLR2 and TLR9 are not required for pancreatitis
induction (Figure 1C). In contrast, Tlr4/mice exhibited a signif-
icant decrease in serum amylase as compared to WT mice. This
is consistent with a report that TLR4 activation is involved in
pancreatitis induction (Sharif et al., 2009). More surprisingly,
however, cerulein-induced elevations in serum amylase concen-
trations were almost completely abrogated in Nod1/ mice
(Figure 1C). These data suggest a critical role for NOD1, which
senses a peptide derived from PGN of the intestinal bacteria in
the induction of high-dose cerulein pancreatitis.
Low-Dose Cerulein Together with NOD1 Ligand Induces
Pancreatitis
We sought an experimental model in which NOD1 ligand admin-
istration could be used as a substitute for MAMPs derived from
gut bacterial flora so that the effects of NOD1 signaling could be
easily isolated from those of cerulein. In searching for such
amodel we became aware that whereas repeated administration
of high doses of cerulein (50–100 mg/kg) induces acute pancrea-
titis as indicated above, administration of low doses of cerulein
does not have this effect, although such doses are still capable
of acinar cell signaling (Baumann et al., 2007; Sharif et al.,
2009). This suggested that low-dose cerulein does not induce
pancreatitis because it does not by itself cause an influx of gut
microorganisms sufficient to result in robust acinar cell NOD1
signaling, and thus low-dose cerulein would cause pancreatitis
if administered with NOD1 ligand. To test this possibility, we
administered FK156 (NOD1 ligand) or muramyl dipeptide
(MDP, NOD2 ligand) (each at a dose of 200 mg i.p.) to C57BL6
mice, 2 hr prior to initiation of a low-dose cerulein regimen con-
sisting of three hourly injections of a dose of cerulein (20 mg/kg
i.p.) that does not induce pancreatitis when administered alone
(Figures 2A and 2B). We found that serum concentrations of
amylase and lipase were markedly elevated in mice treated
with FK156 plus low-dose cerulein, but not in mice treated with
MDP plus low-dose cerulein or in mice treated with either ligand
or cerulein alone (Figure 2B). In addition, pancreatic edema,
necrosis, and infiltration of immune cells were observed in
mice treated with FK156 plus cerulein, but not under the other
conditions (Figures 2C and 2D). Finally, we showed that compa-
rable amounts of serum amylase were obtained when mice wereImmunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc. 327
Figure 1. Bowel Sterilization by a Broad Range of Antibiotics Inhibits Development of Cerulein-Induced Pancreatitis
(A) Changes in serum levels of amylase and lipase in C57BL6 mice treated with or without antibiotics. Mice administered with AMP (1 g/l), neomycin (NEO, 1 g/l),
vancomycin (VCM, 0.5 g/l) andmetronidazole (MNZ, 1 g/l) in the drinking water for 3 weeks were challenged with a high dose of cerulein (50 mg/kg i.p.) for a total of
seven times; results are expressed as means ± SD. **p < 0.01, as compared with group not administered antibiotics.
(B) Histopathology of mice treated with a broad range of antibiotics followed by systemic injection of a high dose of cerulein (50 mg/kg i.p.) for a total of seven
times. Pancreatic tissue was obtained from mice at 8 hr after the first injection of cerulein. Lack of pancreatitis in mice treated with antibiotics, bottom panel.
Magnification 3200.
(C) Changes in serum levels of amylase in Tlr2/, Tlr4/, Tlr9/, or Nod1/ mice without antibiotics. Mice were challenged with a high dose of cerulein
(50 mg/kg i.p.) for a total of seven times. Results are expressed as means ± SD. *p < 0.05, **p < 0.01, as compared with C57BL6 WT mice.
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administration (Figure S2A). Thus, activation of NOD1 causes
severe pancreatitis in mice treated with a low subinflammatory
dose of cerulein, and thus combined low-dose cerulein and
NOD1 ligand could be used as a model to test the role of
NOD1 in cerulein-induced pancreatitis.
We sought to show that NOD1-ligand administration in the
above-described low-dose cerulein model is acting in place of
commensal bacteria. In these studies, C57BL6 mice adminis-
tered drinking water containing AMP and KM were given three
hourly injections of low doses of cerulein alone, an i.p. injection
of ECLACZ alone, or an i.p. injection of ECLACZ and low doses
of cerulein (Figure 2E). Treatment with i.p. injection of ECLACZ
and low-dose cerulein resulted in acute pancreatitis as well as
increased serum amounts of amylase, whereas treatment with
ECLACZ or cerulein alone did not cause significant changes in
these parameters. In additional studies, Nod1/ mice were
more resistant to pancreatitis induced by ECLACZ and low-328 Immunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc.dose cerulein than were WT mice and Tlr4/ mice (Figures 2E
and 2F). Thus, intestinal bacteria evoke a NOD1 response similar
to that obtained with NOD1 ligand, and therefore the latter is
acting as a mimic of intestinal bacteria in this setting.
NOD1 Ligand and Low-Dose Cerulein Are Synergistic
Inducers of MCP-1
Prior work has shown that MCP-1 and interleukin-6 (IL-6) are
associated with the local inflammation of the pancreas (Grady
et al., 1997). We therefore determined the involvement of these
proinflammatory mediators in the development of pancreatitis
induced by FK156 in combination with low-dose cerulein.
Consistent with previous reports (Fritz et al., 2007; Watanabe
et al., 2010), systemic injection of FK156, but not MDP, induced
increased amounts of serum MCP-1 and IP-10 chemokines.
Moreover, MCP-1 induction, but not IP-10 induction, was greatly
enhanced by coadministration of cerulein, even though low-
dose cerulein treatment alone did not induce MCP-1 (Figure 3A).
Figure 2. Induction of Acute Pancreatitis in Mice Treated with NOD1 Ligand or ECLACZ in Combination with Cerulein
(A–D) Induction of acute pancreatitis in mice treated with NOD1 ligand and cerulein.
(A) Experimental protocol: C57BL6 mice were administered FK156 (NOD1 ligand; 200 mg/mice i.p.) or MDP (NOD2 ligand; 200 mg/mice) followed by a low dose of
cerulein (20 mg/kg i.p.) for a total of three times.
(B) Changes in serum levels of amylase and lipase inmice treated with NOD ligands and/or cerulein. Each color corresponds to group shown in Figure 2A. Results
are expressed as means ± SD. *p < 0.01, as compared with other groups.
(C and D) Hematoxylin and eosin (H&E) staining (C) and histological scores (D) of pancreatic tissue harvested at 24 hr after the start of experiments; magnification
3200; each color corresponds to group shown in Figure 2A; scores are expressed as means ± SD. *p < 0.01, as compared with other groups.
(E and F) Induction of acute pancreatitis in mice treated with ECLACZ and cerulein.
(E) Experimental protocol. C57BL6mice and Tlr4/ orNod1/mice exposed to AMP and KM in the drinking water were administered ECLACZ (13 106 cfu, i.p.)
followed by three hourly injections of low doses of cerulein (CER). Changes in serum levels of amylase in C57BL6 mice treated with ECLACZ and/or cerulein, (E),
left panel. Changes in serum levels of amylase in C57BL6 mice and Tlr4/ or Nod1/ mice treated with ECLACZ and cerulein, (E), right panel. Results are
expressed as means ± SD. *p < 0.01, as compared with other groups. Serum levels of amylase were determined 8 hr after the treatment with ECLACZ.
(F) Lack of pancreatitis in Nod1/ mice treated with ECLACZ and cerulein. Magnification 3200.
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that were again enhanced by low-dose cerulein, particularly
at later time points. In contrast, induction of IL-12p40 was
observed either with FK156 or MDP administration, and neither
response was enhanced by low-dose cerulein. Comparable
increases in serum amounts of MCP-1 were observed when
FK156 was administered at the time of or after cerulein adminis-
tration (Figure S2A). These data indicate that the severe pancre-
atitis induced by treatment with NOD1 ligand and low-dose
cerulein is associated with the production of MCP-1 and IL-6.
Finally, similar effects on MCP-1 could be elicited by administra-tion of ECLACZ, in that i.p. administration of the latter followed
by treatment with low doses of cerulein also led to a marked
increase of the serum level of MCP-1 (Figure 3B). In contrast,
Nod1/ mice administered ECLACZ and low doses of cerulein
exhibited little, if any, increase in the serum level of MCP-1
(Figure 3B).
Previous studies have shown that the interaction between
MCP-1 and its receptor, CCR2, plays a role in macrophage
recruitment and the macrophage-dependent inflammatory re-
sponse in the development of pancreatitis (Grady et al., 1997;
Bhatia et al., 2005; Zhao et al., 2005). One might thereforeImmunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc. 329
Figure 3. Concomitant Administration of NOD1 Ligand and Low-Dose Cerulein Induces Synergistic Production of MCP-1
(A) Changes in serum levels of proinflammatory cytokines and chemokines. C57BL6 mice received systemic administration of FK156 or MDP followed by i.p.
injection of cerulein for a total of three times. Results are expressed as means ± SD. *p < 0.01, as compared with other groups. The results shown are repre-
sentative of one of three experiments.
(B) Serum levels of MCP-1 in mice treated with ECLACZ and cerulein. Changes in serum levels of MCP-1 in C57BL6 mice treated with ECLACZ and/or cerulein,
(B), left panel. Changes in serum levels of MCP-1 in C57BL6 mice and Tlr4/ or Nod1/ mice treated with ECLACZ and cerulein, (B), right panel. Results are
expressed as means ± SD. *p < 0.01, as compared with other groups. C57BL6 mice and Tlr4/ or Nod1/mice treated with AMP and KM in the drinking water
were challenged with i.p. injection of ECLACZ followed by three hourly injections of low doses of cerulein. Serum levels of MCP-1 were determined 8 hr after the
treatment with ECLACZ.
Immunity
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cells susceptible to MCP-1 chemoattraction. In tissue-staining
studies (Figure 4A), combined administration of FK156 and
low-dose cerulein was associated with massive infiltration of
CD11b+ myeloid cells and cells expressing CCR2. In contrast,
these cells did not express CXCR3, the receptor of IP-10, indi-
cating the induction of IP-10 by NOD1 probably has little or no
role in this type of inflammation.
The relationship between MCP-1 induction and the infiltration
of the pancreas by CCR2+ cells was further explored through
studies of induction of pancreatitis with FK156 and low-dose
cerulein in CCR2-deficient (Ccr2/) mice. Systemic administra-
tion of FK156 and low-dose cerulein to Ccr2/ mice was asso-
ciated with a marked reduction in the serum amylase level and330 Immunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc.pathology score as compared with WT mice, even though
CCR2-deficient mice were still capable of producing MCP-1
(Figure 4B). In addition, migration of both CD11b+ cells and
CCR2+ cells into the pancreas was absent in Ccr2/mice (Fig-
ure 4C). These studies thus showed that induction of MCP-1 by
FK156 and low-dose cerulein was associated with the infiltration
of inflammatory CCR2+ cells into the inflamed pancreas.
Low-Dose Cerulein Pancreatitis Does Not Depend on
T Cells or B Cells
NOD1 is a component of the innate immune system that
probably involves mainly non-T cells and non-B cells. To deter-
mine if this was in fact the case, we administered FK156
and low-dose cerulein to Prkdcscid mice with severe combined
Figure 4. Migration of CCR2+ Myeloid Cells Is Necessary for the Development of Pancreatitis
(A) At 6 hr after the injection ofMDP or FK156, pancreatic tissue fromC57BL6mice was removed and subjected to immunohistochemical analysis for visualization
of cells positive for CD11b, CCR2, and CXCR3.
(B and C) CCR2-intact (Ccr2+/+) or CCR2-deficient (Ccr2/) mice were administered FK156 followed by repeated administration of cerulein according to the
protocol described in Figure 2A.
(B) Changes in serum levels of amylase and MCP-1 at the indicated time points and pathology scores of the pancreatic tissue at 24 hr; results are expressed as
means ± SD. *p < 0.01, as compared with Ccr2+/+ mice; results shown are representative of one of three experiments.
(C) Pancreatic tissue was removed at 6 hr after the start of the experiments and subjected to immunohistochemical analysis for visualization of cells positive for
CD11b and CCR2; magnification 3200.
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NOD1 and Acute Pancreatitisimmunodeficiency (SCID) that lacked both T cells and B cells.
This treatment induced equally increased amounts of serum
amylase and MCP-1 in WT and SCID mice (Figure S2B), sug-
gesting that the acute pancreatitis induced by systemic injection
of NOD1 ligand and low-dose cerulein does not depend on
T cells or B cells.
Acute Pancreatitis Requires Activation of NOD1 in
Nonhematopoietic Cells
We next turned our attention to the cellular location of the NOD1
involved in the acute pancreatitis model studied above. Our
initial approach to this question was to conduct bone marrow
(BM) chimera studies to determine if NOD1 was acting in hema-
topoietic cells or nonhematopoietic cells for the development of
pancreatitis, but first we had to define the responses of Nod1/
cells to be used in such studies. To this end, we subjected
Nod1/ mice and Nod1+/+ mice to treatment with FK156 or
MDP and low-dose cerulein. Nod1+/+ mice, but not Nod1/mice, developed pancreatitis after such FK156 and cerulein
administration, as evidenced by serum amylase and MCP-1
elevations and histology scores (Figure 5A). These studies indi-
cated that NOD1 stimulation is essential for the induction of
FK156 and low-dose cerulein pancreatitis.
We then performed the BM chimera studies mentioned above
and showed that administration of FK156 and low-dose cerulein
led to pancreatitis in Nod1+/+ green fluorescent protein (GFP)-
transgenicmice reconstitutedwithNod1/BMcells (Figure 5B),
but not in Nod1/ mice reconstituted with Nod1+/+ BM cells.
Thus, the development of FK156 and cerulein acute pancreatitis
involves NOD1 signaling in nonhematopoietic cells.
In a second approach to the identification of the site of NOD1
activity in this model, we conducted in vitro studies of iso-
lated pancreatic acinar cells from untreated mice to determine
whether these cells exhibited NOD1 activity following stimulation
with FK156 and/or low-dose cerulein (Figure S3A). Although
stimulation of acinar cells with FK156 alone induced a substantialImmunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc. 331
Figure 5. The Importance of NOD1 Signaling in Nonhematopoietic Cells for the Development of Severe Acute Pancreatitis
(A)Nod1+/+ orNod1/mice were treated with NOD ligands (FK156 or MDP) and/or cerulein (CER) as described in Figure 2A. Changes in serum levels of amylase
and MCP-1 at the indicated time points, and pancreatitis histology score at 24 hr. *p < 0.01, as compared with the other groups.
(B) BM cells from GFP-transgenic (GFP-Tg) mice or Nod1/mice were transplanted into irradiated GFP-transgenic mice orNod1/mice. These chimeric mice
were treated with FK156 followed by repeated administration of CER. Changes in serum levels of amylase and MCP-1 at the indicated time points, and
pancreatitis histology score at 24 hr. Results are expressed asmeans ± SD. *p < 0.01, as compared with the other groups. *p < 0.01 (pathology score). The results
shown are representative of one of three experiments.
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NOD1 and Acute Pancreatitisamount of MCP-1, synergistic production of MCP-1 was seen
upon stimulation with FK156 plus low-dose cerulein in an
FK156-dose-dependent fashion. In contrast, FK156 alone was
sufficient for the induction of IP-10 production. Finally, the induc-
tion of MCP-1 under these conditions required the presence of
NOD1 (Figure S3B). These studies established, first, that pancre-
atic acinar cells are the nonhematopoietic cellular site of NOD1
activation in the FK156 and low-dose cerulein model of acute
pancreatitis. Second, they showed that MCP-1 induction re-
quires dual NOD1 and low-dose cerulein signaling via NOD1
and CCKR, respectively.
As mentioned in Figure 3A, administration of FK156 and low-
dose cerulein elicited elevations in circulating amounts of IL-6
as well as MCP-1. This finding correlates with the fact that acinar
cells from Nod1+/+ mice, but not cells from Nod1/ mice,
produced IL-6 upon stimulation with FK156 and low-dose ceru-
lein and suggests that, as in the case of MCP-1, increased circu-
lating amounts of IL-6 originate from acinar cells (Figure S3B). It
seemed probable that the MCP-1 and IL-6 secretion might be
interrelated, given that IL-6 participates in MCP-1 production
via STAT3 activation (Deshmane et al., 2009). To address this
possibility, wemeasured acinar cell production of MCP-1 in cells332 Immunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc.isolated from Nod1+/+ mice and then treated with FK156 and
low-dose cerulein in the presence or absence of neutralizing
IL-6 receptor (IL-6R) antibody (Ab). This blockade of IL-6 sig-
naling inhibited the production of MCP-1, but only partially (Fig-
ure S3C); thus, IL-6 is not the only inducer of MCP-1 in this
model.
NOD1 Plus Low-Dose Cerulein Signaling Induces
Transactivation of STAT3 and NF-kB In Vivo
Because acinar cell MCP-1 production is a key factor in the
development of FK156 and low-dose cerulein pancreatitis, we
next turned our attention to the signaling pathways controlling
such production. Previous studies have shown that MCP-1
production depends on STAT3 and NF-kB activation (Deshmane
et al., 2009), and, indeed, we verified that these factors were
necessary for the induction of FK156 and low-dose cerulein
pancreatitis by measuring activation of both STAT3 and NF-kB
in the pancreatic tissue of mice with pancreatitis. Nuclear
expression of phospho-STAT3 (pSTAT3) and phospho-IkBa
(pIkBa) was seen in the pancreatic acinar cells expressing
amylase of Nod1+/+ mice treated with low-dose cerulein and
FK156, whereas little or no pSTAT3 or pIkBa was seen in acinar
Immunity
NOD1 and Acute Pancreatitiscells of Nod1/ mice (Figure S3D). Similar findings were
obtained using conventional immunohistochemical analysis
(Figure S3E).
To confirm the above findings, we performed staining studies
of tissue obtained from BM-chimeric mice, consisting of irradi-
ated Nod1+/+ mice bearing a GFP-expressing transgene and
irradiatedNod1/mice, reconstituted withNod1/GFP-trans-
gene-negative BM cells and Nod1+/+ GFP-transgene-positive
BM cells, respectively. Replacement of BM cells was confirmed
by flow-cytometric analysis of GFP expression at 8 weeks after
the transplantation (Figure S4A). We found that amylase-ex-
pressing acinar cells were GFP-positive in irradiated GFP-trans-
gene-positive mice reconstituted with GFP-transgene-negative
Nod1/BMcells, whereas they wereGFP-negative in irradiated
GFP-transgene-negative Nod1/mice reconstituted with GFP-
transgene-positive Nod1+/+ BM cells (Figure S4B). Thus, the
GFP status of the acinar cells reflected the GFP status of the
recipient, not the donor. In additional studies, we showed that
expression of pIkBa and pSTAT3 was seen in acinar cell nuclei
of irradiated GFP-transgene-positive Nod1+/+ mice reconsti-
tuted with Nod1/ BM cells (Figure S4B). In contrast, expres-
sion of these factors was barely detectable in acinar cell nuclei
of irradiated GFP-transgene-negative Nod1/ mice reconsti-
tuted with GFP-transgene positive Nod1+/+ BM cells (Fig-
ure S4B). Similar findings were obtained using conventional
immunohistochemical analysis (Figure S4C). These data thus
provide additional evidence that activation of STAT3 and NF-
kB in response to FK156 and low-dose cerulein administration
is occurring in pancreatic acinar cells.
Administration of JSI-124, a specific STAT3 inhibitor, inhibited
nuclear translocation of STAT3, and administration of IMD-0354,
an NF-kB inhibitor, inhibited nuclear translocation of the NF-kB
subunit p65 in the pancreas of mice administered FK156 and
low-dose cerulein, as assayed in the Transfactor Binding Assay,
establishing that these agents do in fact exert the expected inhi-
bition of activation of STAT3 and NF-kB under these conditions
(Figure S5A). In addition, administration of JSI-124 or IMD-0354
alone led to a partial reduction of serum levels of amylase and
MCP-1, whereas administration of both agents led to complete
reduction of serum levels of amylase and MCP-1 (Figure S5B).
A similar result was obtained in respect to the inflammation score
of the pancreas (Figure S5C). These studies, using pharmaco-
logical inhibitors for STAT3 and NF-kB, thus provide evidence
that activation of both STAT3 and NF-kB in acinar cells acts in
an additive fashion to bring about the development of pancrea-
titis induced by FK156 and low-dose cerulein.
Molecular Mechanisms Underlying the Activation of
STAT3 and NF-kB in FK156 and Low-Dose Cerulein
Pancreatitis
Having established that STAT3 and NF-kB are critical signaling
components in the induction of FK156 and low-dose cerulein
pancreatitis, we were interested in establishing how FK156 and
low-dose cerulein act together to induce these components,
whereas neither stimulant do so alone. In initial studies we
focused on the signaling pathways leading to STAT3 activation
and showed that treatment with FK156 alone induced expres-
sion of pSTAT3 in the pancreas of Nod1+/+ mice, but not
Nod1/ mice (Figure 6A). This is consistent with our previousreport that NOD1 ligand induces type I IFN production (Wata-
nabe et al., 2010) as well as with a study showing that type I
IFN activates various STATs, including STAT3 (Yang et al.,
1998). Similarly, treatment with cerulein alone induced pSTAT3
expression (in both Nod1+/+ and Nod1/ mice), presumably
as a result of direct CCKR activation of JAK2 (Ferrand et al.,
2005). However, treatment of Nod1+/+ mice (but not Nod1/
mice) with both FK156 and low-dose cerulein induced higher
pSTAT3 expression as compared with either stimulus alone,
and this was associated with similarly increased nuclear translo-
cation (Figure 6B). Thus, FK156 and low-dose cerulein reinforce
one another in STAT3 activation.
We also noted that expression of pSTAT1 was induced in the
pancreas of Nod1+/+ mice treated with FK156, but, in this case,
such expression was not enhanced by combined treatment with
FK156 and cerulein (Figure 6A). Moreover, expression of pSTAT1
was not induced in the pancreas of Nod1/mice, whether mice
were treated with FK156 or cerulein. These results were corrob-
orated by measurement of nuclear translocation (Figure 6B).
Given the fact that STAT1 is a critical downstream signaling
molecule for type I IFN, these data suggest that FK156 also acti-
vates a type I IFN pathway, as reported previously (Watanabe
et al., 2010).
We next examined the signaling pathways leading to NF-kB
activation. Although previous studies utilizing human embryonic
kidney cells showed rapid activation of NF-kB upon stimulation
with NOD1 ligands (Chamaillard et al., 2003; Fritz et al., 2007),
the roles of NF-kB in NOD1-mediated signaling pathways have
been poorly defined in primary pancreatic acinar cells. In initial
studies, we found that neither NOD1 ligand nor low-dose ceru-
lein administration alone resulted in expression of pIkBa or
degradation of IkBa (Figure 6A). This is consistent with our
previous report that NOD1 stimulation alone is a poor inducer
of NF-kB in intestinal epithelial cells (Watanabe et al., 2010) as
well as previous reports by other investigators that cerulein is
also a poor inducer of NF-kB at low concentrations (Yu et al.,
2005). Nevertheless, combined stimulation did result in such
induction as shown by expression of pIkBa and nuclear translo-
cation of p65 and p50 (Figures 6A and 6B). In explanation of this
finding, we focused first on CCK signaling and noted that
previous studies had shown that CCKR signaling induces protein
kinase C (PKC) activation (Rakonczay et al., 2008; Tando et al.,
1999). To verify that this pathway is in play in the low-dose cer-
ulein model we treated mice with low-dose cerulein (in the pres-
ence or absence of FK156) and showed that suchmice exhibited
enhanced pancreatic cell expression of phospho-PKC (pPKC)
(Figure 6A). Because both activated PKC generated by cerulein
signaling and RICK (receptor-interacting protein-like interacting
caspase-like apoptosis regulatory protein kinase) generated by
NOD1 signaling are known to activate NF-kB via phosphoryla-
tion and/or ubiquitination of transforming growth factor b (TGF-
b)-activated kinase 1 (TAK1) (Hasegawa et al., 2008; Shinohara
et al., 2005), we next considered the possibility that TAK1 is a
signaling molecule that serves as a nodal point in the low-dose
cerulein and FK156 signaling pathways that facilitate NF-kB acti-
vation. In studies to explore this possibility, we performed immu-
noprecipitation studies of cell lysates isolated from the pancreas
of Nod1+/+ and Nod1/ mice. We found that treatment with
cerulein, but not FK156, induced physical interaction betweenImmunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc. 333
Figure 6. NOD1 Activation Followed by Cerulein Challenge Induces Transactivation of STAT3 and NF-kB In Vivo
Nod1+/+ orNod1/mice were treatedwith FK156 and/or cerulein (CER) as described in Figure 2A.Whole or nuclear extracts were prepared from the pancreas of
mice at 5 hr after systemic challenge with FK156 and subjected to immunoblotting.
(A) The expression of pSTAT3, STAT3, pSTAT1, STAT1, pPKC, PKCd, pIkBa, IkBa, and actin was shown with the use of whole-pancreatic extract.
(B) Activation of STAT1, STAT3, p65, and p50with the use of nuclear extracts, as assessed by Transfactor assay. Results are expressed asmeans ± SD. *p < 0.01,
as compared with the untreated group. The results shown are representative of one of three experiments.
(C) Physical interaction betweenRICK and TAK1 or between PKCd and TAK1 in whole-pancreatic extracts. Pancreatic extracts were immunoprecipitated (IP) with
TAK1 Ab, followed by immunoblotting (IB) with PKCd or RICK Ab.
Immunity
NOD1 and Acute PancreatitisTAK1 and PKCd in pancreatic cells of Nod1+/+ and Nod1/
mice (Figure 6C), suggesting induction of TAK1 activation
through cerulein-mediated PKC activation. More importantly,
as shown by immunoprecipitation with TAK1 Ab followed by
immunoblotting with RICK Ab, interaction between RICK and
TAK1 was markedly increased in the pancreas of mice treated
with both FK156 and low-dose cerulein as compared to the
marginal interaction observed with FK156 alone (Figure 6C).
Taken together, these data are consistent with the hypothesis
that synergistic NF-kB activation by low-dose cerulein and
NOD1 is due to cerulein-induced PKC-TAK1 activation followed
by opportunistic RICK utilization of the activated TAK1 to induce
NF-kB.
NOD1-Induced Activation of STAT3 via Type I IFN
Finally, to more fully assess the role of NOD1 signaling in STAT3
activation via type I IFN, we investigated FK156 and low-dose
cerulein induction of pancreatitis in IFN-ab receptor (IFN-abR)-
deficient (Ifnar1/) mice. In initial studies, we showed that
Ifnar1/ mice exhibited an attenuated pancreatitis along with334 Immunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc.a significant reduction of serum levels of amylase and MCP-1
as compared with those in Ifnar1+/+ mice (Figures 7A and 7B).
In addition, upon challenge with FK156 and low-dose cerulein,
pancreatic expression of pSTAT3 in Ifnar1/ mice was signifi-
cantly reduced as compared to that in Ifnar1+/+ mice, suggesting
that type I IFN signaling is necessary for maximal STAT3 activa-
tion in this model (Figure 7C).
As expected, pancreatic expression of pSTAT1 was com-
pletely absent in Ifnar1/ mice upon challenge with FK156
and low-dose cerulein, suggesting that pancreatic STAT1 acti-
vation is dependent upon NOD1-mediated type I IFN signaling
in this model. In addition, consistent with the results of the
signaling studies presented above, no significant difference
in NF-kB activation was seen between Ifnar1/ and Ifnar1+/+
mice, as assessed by pancreatic expression of pIkBa and
IkBa. Serum levels of IFN-b and IP-10, whose production re-
quires activation of type I IFN signaling, were markedly reduced
in Ifnar1/ mice treated with FK156 and low-dose cerulein as
compared with those in Ifnar1+/+ mice. In contrast, no significant
difference was seen in production of IL-6, whose production
Figure 7. Involvement of Type I IFN Signaling in the Development of Pancreatitis
(A–C) IFNab receptor-intact (Ifnar1+/+) or -deficient (Ifnar1/) mice were subjected to induction of FK156 and low-dose cerulein pancreatitis, as indicated in
Figure 2.
(A and B) Serum levels of amylase (A) andMCP-1, IL-6, IFN-b, and IP-10 (B) at 6 hr after systemic challenge with FK156 and pathology scores (A) of the pancreatic
tissue at 24 hr after systemic challenge with FK156. Results are expressed as means ± SD. *p < 0.01, as compared with Ifnar1+/+ mice.
(C) Whole-cell extracts were prepared from pancreatic tissue of mice at 5 hr after systemic challenge with FK156 and subjected to immunoblotting to determine
expression of pSTAT3, STAT3, pSTAT1, STAT1, pIkBa, IkBa, and actin. The results shown are representative of one of two experiments.
(D and E) C57BL6 mice were subjected to induction of FK156 and low-dose cerulein pancreatitis; blood and peritoneal lavage fluid were collected 8 hr after the
injection.
(D) Percentage and number (parentheses) of mice that were positive for bacterial culture in the blood and peritoneal lavage fluids.
(E) Bacterial loads in the blood determined by counting colonies in columbia agar, trypticase soy agar, and chocolate agar plates. Results are expressed as
means ± SD and a summary of three independent experiments.
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results indicate that type I IFN signaling induced by NOD1
activation is involved in the development of pancreatitis in this
model.
Bacterial Translocation in Low-Dose Cerulein-Induced
Pancreatitis
Intestinal barrier dysfunction and translocation of intestinal
microflora into the systemic circulation play a critical role in
the development of severe acute pancreatitis (Frossard et al.,
2008; Rychter et al., 2009). We therefore addressed the role of
bacterial translocation with studies of bacteremia inmice treated
with low-dose cerulein alone or in combination with FK156. Wefound that 5 of 7 mice treated with low-dose cerulein alone ex-
hibited bacteremia, but that the level of bacteremia was relatively
low in each case (Figures 7D and 7E). On the other hand, 6 of 7
mice subjected to combined treatment with FK156 and low-dose
cerulein exhibited bacteremia, and in this case, the level of
bacteria was much higher than that obtained by treatment with
low-dose cerulein alone.
To more clearly identify the role of bacterial translocation from
the gut into the circulation in low-dose cerulein pancreatitis, we
treated mice with drinking water containing AMP and KM and
administered oral ECLACZ prior to FK156 and low-dose cerulein
administration. We again observed bacteremia, in this case at
a level that increased in parallel with the oral ECLACZ doseImmunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc. 335
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NOD1 and Acute Pancreatitis(Figure S6). As expected, the peak level of bacteremia was not as
high as that obtained with normal ‘‘unperturbed’’ microflora in
the initial study, probably due to the relative paucity of organisms
present in the gut under these circumstances. However, it should
be noted that serum amylase levels increased in proportion to
the oral ECLACZ dose, indicating that even these relatively low
levels of bacteremia supported the development of pancreatitis
in mice that were administered FK156 and low-dose cerulein
(Figure S6). These data are consistent with the view that low-
dose cerulein administration alone does not induce pancreatitis
in the absence of NOD1 ligand and, in addition, does not induce
sufficient bacterial translocation to facilitate de novo NOD1 acti-
vation due to exposure to low levels of translocated organisms.
In contrast, FK156 and low-dose cerulein administration not only
initiated pancreatitis, but also caused bacterial translocation that
can now sustain the pancreatitis.
DISCUSSION
We explored the mechanism by which commensal intestinal
bacteria contribute to the development of pancreatitis induced
by cerulein, a CCKR agonist. Our initial studies established
that high-dose cerulein administration, capable of causing pan-
creatitis by itself, required the presence of a normal intestinal
bacterial flora and, quite surprisingly, acted via stimulation of
NOD1, an intracellular sensor of a peptide derived from the
bacterial wall of both gram-positive and -negative bacteria. To
further study this phenomenon, we developed a model of pan-
creatitis in which mice were administered a dose of cerulein
that by itself was insufficient to cause pancreatitis but was never-
theless able to cause pancreatitis when coadministered with
NOD1 ligand. This model thus allowed us to identify the specific
roles of cerulein and NOD1 signaling in the induction of pancre-
atic inflammation.
Two key immunopathologic features of the pancreatitis in
the low-dose cerulein model are that the inflammation is associ-
ated with acinar cells that produce large amounts of MCP-1,
a chemoattractant of CCR2+ cells, and that Ccr2/ mice
are almost completely resistant to the development of pancrea-
titis in this model. These findings strongly suggest that the pan-
creatitis is driven by MCP-1-mediated migration of CCR2+
inflammatory cells into the pancreas. This conclusion is consis-
tent with previous studies showing that abrogation of MCP-
1:CCR2 interactions via administration of a plasmid expressing
mutated MCP-1 or a blocker of MCP-1 synthesis protects ani-
mals from experimental pancreatitis (Bhatia et al., 2005; Zhao
et al., 2005). In addition, in a clinical study, Regne´r et al. (2008)
showed that serum levels of MCP-1 at the time of a patient’s
admission to hospital are strongly associated with development
of severe acute pancreatitis. Thus, it appears that acinar cell
production of MCP-1 and MCP-1-dependent cell migration are
essential to the development of acute pancreatitis, not only in
this model, but also in other models, and in human pancreatitis
as well.
The importance of MCP-1 to pancreatitis accounts for the
need for NOD1 signaling in the induction and maintenance of
this inflammation. Previous studies have shown that activation
of both NF-kB and STAT3 is required for maximal production
ofMCP-1 (Deshmane et al., 2009; Ray et al., 2008). In the present336 Immunity 37, 326–338, August 24, 2012 ª2012 Elsevier Inc.studies, we corroborated this finding in the context of pancrea-
titis by showing that both the NF-kB and STAT3 signaling
pathways are activated during MCP-1 induction and, indeed,
pharmacological inhibition of both pathways is required for the
suppression of pancreatitis. In addition, we found that although
FK156 or cerulein could induce STAT3 alone, both were neces-
sary for optimal induction and, perhaps more importantly,
although neither stimulant could induce activation of the NF-kB
signaling pathway alone, they could induce this pathway when
acting in concert. It follows that NOD1 signaling is essential to
pancreatitis induction because it is necessary for robust activa-
tion of the signaling pathways that lead to the production of
MCP-1.
The poor NF-kB activation by NOD1 signaling alone in the
present study is consistent with our previous studies of this
signaling pathway. We showed in these studies that NOD1 acti-
vation of RICK (the adaptor protein immediately downstream of
NOD1) leads to RICK binding to TRAF3, and thus to activation of
TBK1 and IRF7; this, in turn, leads to induction of IFN-b and
signaling via IFNabR for inducing IFN-stimulated gene factor
3, a complex composed of STAT1, STAT2, and IRF9 that acts
as a transcription factor for chemokines including IP-10 (Wata-
nabe et al., 2010). Thus, in effect, NOD1 signaling bypasses
NF-kB to induce chemokines via a type I IFN-dominated
pathway. How, then, does NOD1 signaling cause NF-kB activa-
tion in association with low-dose cerulein? We believe the
answer lies in the fact that even low doses of cerulein induce
activation of TAK1 via PKC (Li et al., 2009; Shinohara et al.,
2005) and that in the presence of such activation, RICK acti-
vated by NOD1 forms a complex with TAK1 to activate NF-kB.
This idea is supported by an enhanced physical interaction
between RICK and TAK1 in the mice treated with both FK156
and cerulein.
With respect to STAT3 activation in this model, previous
studies have shown that cerulein can induce STAT3, at least at
suboptimal levels (Yu et al., 2005). However, as shown in these
studies, NOD1 signaling greatly augments such induction by at
least two mechanisms. On the one hand, by facilitating NF-kB
activation, NOD1 promotes the synthesis of IL-6, a cytokine
capable of STAT3 activation. On the other hand, NOD1 signaling
leads to production of type I IFN, a cytokine also capable of
STAT3 activation (Yang et al., 1998).
Analysis of the level of bacteremia occurring after administra-
tion of a low dose of cerulein alone or in combination with NOD1
ligand provided insight into the role of bacterial entry into the
circulation in the induction of low-dose cerulein pancreatitis.
Low-level bacteremia was observed in mice treated with low
doses of cerulein alone, indicating that the level of activation
of CCKR with this dose leads to some degree of translocation
of bacteria into the systemic circulation. Evidently, however,
this level of translocation does not provide a sufficient NOD1
signal in acinar cells to initiate and sustain pancreatitis. In con-
trast, higher levels of bacteremia accompanied administration
of NOD1 ligand and low-dose cerulein. It appears that such
bacteremia, by providing a continued source of NOD1 signaling,
is necessary to sustain the pancreatitis initiated by exogenous
NOD1 ligand. Thus, low-dose cerulein-induced pancreatitis is
equivalent to high-dose cerulein pancreatitis, except for the
fact that the latter initiates a level of pancreatic inflammation
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on its own.
It has been generally assumed that NOD1 activation is induced
exclusively by pathogenic organisms and that such activation
elicits NOD1-mediated host defense responses (Girardin et al.,
2003; Kim et al., 2004). However, it was recently shown that
NOD1 signaling can also be initiated by commensal organisms
in the neonatal gut, where it plays a role in lymphoid-tissue
organogenesis via the induction of defensin and the production
of a chemotactic factor (Bouskra et al., 2008). The present study
extends this observation by showing that NOD1 activation by
commensal organisms also occurs during an inflammatory
response. These observations raise the question of why NOD1
activation by commensal organisms does not cause inflamma-
tion in the normal gut. We believe the answer to this question
is that NOD1 does respond to commensal organisms in the
normal uninflamed gut via type I IFN signaling rather than NF-
kB signaling, and type I IFN signaling does not result in inflamma-
tion (Abe et al., 2007).
In conclusion, in the present study, we provide evidence that
activation of NOD1 by commensal organisms can facilitate a
severe form of acute pancreatitis by acting in synergy with low
doses of a CCKR agonist, cerulein. In addition, we show that
such synergy is necessary for the production of MCP-1, a
chemokine that mediates migration and infiltration of CCR2+
pathogenic myeloid cells into the pancreas. Finally, we show
that a critical feature of this model of pancreatitis, as well as
high-dose cerulein pancreatitis, that does not require priming
by NOD1 agonist, is that pancreatitis is driven by commensal
organisms that stimulate NOD1 in acinar cells. Thus, although
autodigestion of acinar cells mediated by activation of pancre-
atic enzymes such as trypsinogen is one necessary component
of acute pancreatitis, bacterial translocation and the induction
of acinar cell expression of inflammatory mediators are also
necessary components (Dawra et al., 2011; Ji and Logsdon,
2011). It seems probable that therapeutic measures attacking
these latter components, such as those directed at the inhibition
of NOD1 signaling, offer a new approach to the treatment of
acute pancreatitis.EXPERIMENTAL PROCEDURES
Mice
C57BL6 mice, GFP-transgenic mice (Okabe et al., 1997), and Prkdcscid mice
were purchased fromCLEA. Tlr2/, Tlr4/, and Tlr9/mice were purchased
from Oriental Bioservice. In some experiments, Nod1/ (Watanabe et al.,
2010) and Ccr2/ mice (Boring et al., 1998) were used. Mice were reared
under specific pathogen-free conditions. Animal use adhered to the Kyoto
University animal-care guidelines, and protocols of animal experiments were
approved by the review boards of Kyoto University.
Induction of Pancreatitis
Mice received i.p. injection of FK156 (200 mg) or MDP (200 mg) in combination
with i.p. injection of cerulein (20 mg/kg) for a total of three times. Mice treated
with AMP (1 g/l) and KM (1 g/l) in the drinking water for 2 weeks were chal-
lenged with i.p. injection of ECLACZ (Yoshida et al., 2001) (1 3 106 cfu) fol-
lowed by i.p. injection of cerulein (20 mg/kg) for a total of three times. Mice
treated with AMP (1 g/l), neomycin (1 g/l), KM (0.5 g/l), or metronidazole
(1 g/l) in the drinking water for 3 weeks were challenged with i.p. injection of
cerulein (50 mg/kg) for a total of seven times. Sera and pancreas tissue were
obtained at the indicated time points.Bone Marrow Transplantation
For the generation of BM-chimeric mice, recipient mice were irradiated with
10 Gy and were reconstituted with BM cells from the donor mice as previously
described (Watanabe et al., 2010).
NF-kB and STAT3 Activation Assay
Whole extracts isolated from the pancreas were subjected to immunoblotting
as previously described (Watanabe et al., 2010). pSTAT1, STAT3, pSTAT3,
IkBa, pIkBa, pPKC, and PKCd Abs were obtained from Cell Signaling. Actin,
TAK1, and STAT1 Abs were obtained from Santa Cruz Biotechnology. Binding
activity of nuclear extract to NF-kB subunits (p50 and p65), STAT1, and STAT3
was measured using a TransAM kit, obtained from Active Motif, as previously
described (Watanabe et al., 2010). 7 or 15 mg of nuclear extracts were sub-
jected to assay. Physical interaction between RICK and TAK1 or between
PKCd and TAK1 was analyzed via immunoprecipitation using whole-pancre-
atic extract. Pancreatic extracts were immunoprecipitated with TAK1 Ab
followed by immunoblotting with PKCd or RICK Ab (Cayman) as described
previously (Watanabe et al., 2010).
Statistical Analysis
Student’s t test was used to evaluate the significance of the differences. A
value of p < 0.05 was regarded as statistically significant.
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